Keros Therapeutics Inc’s filing revealed that its Chief Financial Officer Regnante Keith unloaded Company’s shares for reported $1.81 million on Nov 04 ’23. In the deal valued at $45.29 per share,40,000 shares were sold. As a result of this transaction, Regnante Keith now holds 0 shares worth roughly $0.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oppenheimer initiated its Keros Therapeutics Inc [KROS] rating to an Outperform in a research note published on June 25, 2024; the price target was $102. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in late February with a ‘”an Outperform”‘ rating. Wells Fargo began covering KROS with “an Overweight” recommendation on December 08, 2023. Wedbush started covering the stock on July 31, 2023. It rated KROS as “an Outperform”.
Price Performance Review of KROS
On Tuesday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -2.19% to $42.81. Over the last five days, the stock has lost -6.22%. Keros Therapeutics Inc shares have risen nearly 7.67% since the year began. Nevertheless, the stocks have risen 6.55% over the past one year. While a 52-week high of $73.00 was reached on 02/29/24, a 52-week low of $27.02 was recorded on 01/02/24. SMA at 50 days reached $51.04, while 200 days put it at $47.16. A total of 0.34 million shares were traded, compared to the trading of 1.19 million shares in the previous session.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 42.20, which if violated will result in even more drops to 41.58. On the upside, there is a resistance level at 43.62. A further resistance level may holdings at 44.42. The Relative Strength Index (RSI) on the 14-day chart is 30.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.63%. Stochastics%K at 15.63% indicates the stock is a buying.
The most recent change occurred on July 26, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $65 price target.
